| ID | 10009 |
| Vaccine Name | Sinopharm Vaccine (Vero cell inactivated) |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Live-attenuated |
| Vaccine Status | Approved |
| Manufacturer | Sinopharm |
| Year of Manufacturing | 2020 |
| Manufacturing Country | China |
| Age | NA |
| Dosage | 2 doses 14 or 21 days apart |
| Administration Route | Intramuscular |
| Adjuvant | Aluminum (alum) |
| Target Strain | NA |
| Description | NA |
| Approving Organisation | WHO |
| Collaborating Organisation | NA |
| Other Countries | Jordan, Bahrain, Morocco, UAE |
| Trade Name | NA |
| PMID | 32328406 |
| Clinical Trial ID | NA |
| Reference Link | https://pubmed.ncbi.nlm.nih.gov/32328406/ |
| Additional Links | https://covid19.health.gov.mv/wp-content/uploads/2021/10/SINOPHARM-INFORMATION-SHEET_Final-Revised-09th-June.pdf
|